GlassScriptPhysician profile
Kathryn W Dudas
NPI 1164683058
$14,498.60
in general payments reported to CMS, 2019-2025
41 companies · $966 in 2025
The $966 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,627 · 2020: $868 · 2021: $1,834 · 2022: $2,121 · 2023: $5,297 · 2024: $1,786 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,025 · Food and Beverage: $4,004 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,025.00 |
| Food and Beverage | $4,004.13 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,907.77 | 2019-2024 | Qulipta, Ubrelvy, Synthroid |
| Novo Nordisk INC | $2,162.00 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $1,096.37 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $1,079.03 | 2019-2025 | Evenity, Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $650.83 | 2019-2025 | Trintellix |
| Pfizer INC. | $562.10 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $479.82 | 2019-2025 | Farxiga, Airsupra |
| Supernus Pharmaceuticals, INC. | $476.24 | 2020-2024 | Qelbree, Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $383.82 | 2019-2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $309.07 | 2019-2025 | Austedo Xr, Ajovy |
| Phathom Pharmaceuticals, INC. | $280.50 | 2024-2025 | Voquezna |
| Abbott Laboratories | $225.46 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $203.15 | 2019-2025 | Lagevrio |
| Biohaven Pharmaceutical Holding Company LTD. | $196.45 | 2022 | |
| Idorsia Pharmaceuticals US INC | $180.15 | 2022-2025 | Quviviq, Quviviq |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Dudas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.